PMC Group Announces Agreement To Acquire Lanxess’ Organotin Specialties Business
Wednesday, 13 November 2019
MOUNT LAUREL, NJ (November 13, 2019) – PMC Group N.A., Inc. (“PMC”) and Lanxess Organometallics GmbH are pleased to announce that the parties have reached an agreement whereby PMC’s European subsidiary will acquire the organotin specialties product line (the “Business”) from Lanxess. The transaction is scheduled to close by year end, subject to customary closing
- Published in News
No Comments
PMC Group International Announces Acquisition of Product Line from Solvay S.A.
Wednesday, 16 January 2019
MOUNT LAUREL, NJ (January 16, 2019) – PMC Ouvrie SAS, France, a wholly owned subsidiary of PMC Group International Inc., which is an independent arm of PMC Group Inc., announced the acquisition of a hydrocolloid product line from the Belgium based Solvay, SA. These products will be sold globally to the home and personal care
- Published in News
Polypeptide Therapeutic Solutions and PMC Isochem Sign Business and Technology Collaboration Agreement in the Field of Cosmetic and Therapeutic Polypeptide.
Monday, 12 March 2018
VERT-LE-PETIT, FRANCE (March 12, 2018) – Under the agreement, Polypeptide Therapeutic Solutions will use proprietary technology and research capabilities to offer contract research services from the polypeptide design up to delivery of small quantity of polymer and PMC Isochem will use GMP production facility for clinical batch and commercial supply. In addition, PMC Isochem develops
- Published in News
PMC Biogenix Announces Price Increase on Certain Product Lines
Wednesday, 06 December 2017
MEMPHIS, TN (December 5, 2017) — PMC Biogenix Inc. announces that effective January 1, 2018 or as contracts permit, prices for products sold under the trademarks Armoslip®, Hystrene®, Industrene®, Kemamide®, Kemester®, and Lubrazinc® will increase by 3% (three percent). Customers with questions should contact their sales manager or their local customer service contact. About
- Published in News